Kiniksa Pharmaceuticals International Financial Ratios
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kiniksa Pharmaceuticals International ratio analysis
Kiniksa Pharmaceuticals International earned a net margin of 8.7% in FY 2025, up from -10.2% a year earlier. Gross margin was 88.5% compared with a median of 86.6% over the prior 4 years. Return on equity reached 10.4%, meaning Kiniksa Pharmaceuticals International generated 0.10 dollars of profit for every dollar of shareholders' equity.
At the end of FY 2025, KNSA traded at 56.0 times earnings; across the 3 fiscal years shown, its year-end P/E ranged from 5.8 to 87.7, with a median of 56.0. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Kiniksa Pharmaceuticals International financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 56.01 | — | 87.70 | 5.76 | — | — | — | — | — |
| Price / sales | 4.60 | 3.43 | 4.55 | 4.72 | 20.94 | — | — | — | — |
| Price / book | 5.49 | 3.31 | 2.80 | 2.62 | 4.36 | 3.50 | 2.94 | 2.75 | — |
| Gross margin | 88.5% | 85.6% | 87.6% | 89.6% | 76.4% | — | — | — | — |
| Operating margin | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% | — | — | — | — |
| Net margin | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | — | — | — | — |
| Free cash flow margin | 20.1% | 6.0% | 4.9% | 2.6% | -328.7% | — | — | — | — |
| Return on equity (ROE) | 10.4% | -9.9% | 3.2% | 46.3% | -85.3% | -51.7% | -71.8% | -37.0% | — |
| Return on assets (ROA) | 7.7% | -7.4% | 2.7% | 39.9% | -67.8% | -46.2% | -63.6% | -32.1% | -136.6% |
| Current ratio | 3.79 | 3.30 | 4.34 | 5.16 | 4.38 | 10.46 | 8.68 | 7.37 | 2.70 |
| Revenue growth | 60.1% | 56.6% | 22.7% | 471.2% | — | — | — | — | — |
| EPS growth | — | -400.0% | -92.3% | — | — | — | — | — | — |